BioPlex 2200 system to diagnostic test to detect rheumatoid arthritis has been launched in markets by Axis-Shield and Bio-Rad.
Intellikine has begun the first in man studies of its oral, targeted cancer drug INK128, the company announced.
VB-201, an oral immune response modifier pill to treat psoriasis, has entered phase 2 human studies.
US FDA has given priority review for pulmonary fibrosis drug pirfenidone, Intermune Inc has said in a press announcement.
Protandim stimulates the body's production of its own powerful antioxidant enzymes